Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer

Cancer Detection and Prevention

Volumn 26, Issue 2, 2002, Pages 149-157

  Sauter, Edward R ^a   Chervoneva, Inna ^a   Diamandis, Anastasia ^c   Khosravi, Javad M ^c,d   Litwin, Samuel ^b   Diamandis, Eleftherios P ^d,e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Diagnostic Systems Laboratories   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Breast cancer screening; Nipple aspirate fluid; Prostate specific antigen; Risk factors for breast cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; BODY FLUID; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; NIPPLE; SECRETION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BODY FLUIDS; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MIDDLE AGED; NIPPLES; PROSTATE-SPECIFIC ANTIGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036909183     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00028-4     Document Type: Article

References (31)

1. Harris JR, Morrow M, Bonnadonna G. Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1993;1633-1726.
2. Sauter ER, Daly M, Linahan K, et al. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5(12):967-70.
3. Helle SI, Holly JM, Tally M, et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996;69(4):335-9.
4. Bruning PF, Van Doorn J, Bonfrer JM, et al. Insulin-like growth-factor-binding protein-3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62(3):266-70.
5. Baxter RC, Hizuka N, Takano K, et al. Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I. Acta Endocrinol (Copenh) 1993;128(2):101-8.
6. Neely EK, Rosenfeld RG. Insulin-like growth factors (IGFs) reduce IGF-binding protein-4 (IGFBP- 4) concentration and stimulate IGFBP-3 independently of IGF receptors in human fibroblasts and epidermal cells. Endocrinology 1992;130(2):985-93.
7. Oh Y, Gucev Z, Ng L, et al. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res 1995;6(2/4):503-12.
8. Gill ZP, Perks CM, Newcomb PV, et al. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 1997;272(41):25602-7.
9. Yu H, Levesque MA, Khosravi MJ, et al. Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer 1998;79(6):624-8.
10. Rocha RL, Hilsenbeck SG, Jackson JG, et al. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 1996;88(9):601-6.
11. Figueroa JA, Jackson JG, McGwire WL, et al. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 1993;52(2):196-205.
12. Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27(2):75-9.
13. Sauter ER, Ross E, Daly M, et al. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. Br J Cancer 1999;81(7):1222-7.
14. Okabe E, Kajihara J, Usami Y, et al. The cleavage site specificity of human prostate-specific antigen for insulin-like growth factor binding protein-3. FEBS Lett 1999;447(1):87-90.
15. Lalou C, Binoux M. Evidence that limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3) occurs in the normal state outside of the bloodstream. Regul Pept 1993;48(1/2):179-88.
16. Lee KO, Oh Y, Giudice LC, et al. Identification of insulin-like growth factor-binding protein-3 (IGFBP- 3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: A comparison of normal and vasectomized patients. J Clin Endocrinol Metab 1994;79(5):1367-72.
17. Lalou C, Lassarre C, Binoux M. Isolation and characterization of proteolytic fragments of insulin-like growth factor-binding protein-3. Horm Res 1996;45(3-5):156-9.
18. Booth BA, Boes M, Dake BL, et al. Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3. Am J Physiol 1999;276(3 Part 1):E450-4.
19. Black MH, Magklara A, Obiezu C, et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2) in breast tumours and in normal breast secretions. Br J Cancer 2000;82(2):361-7.
20. Agurs-Collins T, Adams-Campbell LL, Kim KS, et al. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev 2000;24(3):199-206.
21. Elmlinger MW, Grund R, Buck M, et al. Limited proteolysis of the IGF binding protein-2 (IGFBP-2) by a specific serine protease activity in early breast milk. Pediatr Res 1999;46(1):76-81.
22. McCullagh P, Nelder JA. Generalized Linear Models. New York: Chapman & Hall, 1991.
23. Keynes G. Chronic mastitis. Br J Surg 1923;11:89-121.
24. Petrakis NL, Mason L, Lee R, et al. Association of race, age, menopausal status, and cerumen type with breast fluid secretion in nonlactating women, as determined by nipple aspiration. J Natl Cancer Inst 1975;54(4):829-34.
25. King EB, Barrett D, King MC, et al. Cellular composition of the nipple aspirate specimen of breast fluid. I. The benign cells. Am J Clin Pathol 1975;64(6):728-38.
26. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351(9113):1393-6.
27. Yang Y, Chisholm GD, Habib FK. The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate. Prostate 1992:21(3):201-8.
28. Stege RH, Tribukait B, Carlstrom KA, et al. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 1999;38(3):183-8.
29. Scanlon EF. Breast cancer. In: Holleb Al, Fink DJ, Murphy GP, editors. Textbook of Clinical Oncology. Atlanta: The American Cancer Society, 1991. p. 177-93.
30. Mannello F, Malatesta M, Sebastini M, et al. Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids. Clin Chem 1999;45(12):2263-6.
31. Zhao Y, Verselis SJ, Klar N. Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. J Clin Oncol 2001;19(5):1462-7.